Hope for rare immune disorder: long-term drug safety tested

NCT ID NCT02859727

Terminated Disease control Sponsor: Pharming Technologies B.V. Source: ClinicalTrials.gov ↗

First seen Mar 31, 2026 · Last updated May 23, 2026 · Updated 12 times

Summary

This study looked at the long-term safety and effectiveness of the drug CDZ173 in people with APDS/PASLI, a rare genetic condition that weakens the immune system. Participants had either been in a previous study or had taken similar drugs before. The goal was to see how well the drug controlled the disease over time, but the study was stopped early.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Pharming Investigative Site

Bethesda, Maryland, 20892, United States
Pharming Investigative Site

Minsk, 223053, Belarus
Pharming Investigative Site

Prague, CZE, 15006, Czechia
Pharming Investigative Site

Dresden, 01307, Germany
Pharming Investigative Site

Brescia, BS, 25123, Italy
Pharming Investigative Site

Palermo, PA, 90127, Italy
Pharming Investigative Site

Rotterdam, 3000 CA, Netherlands
Pharming Investigative Site

Moscow, 117198, Russia

Conditions

Explore the condition pages connected to this study.

ACTIVATED PI3KDELTA SYNDROME (APDS); PASLI DISEASE